Scarica l'app Stockscreener
2.70
1.89%
0.05
Pre-mercato:
2.68
-0.02
-0.74%
Precedente Chiudi:
$2.65
Aprire:
$2.65
Volume 24 ore:
2.24M
Relative Volume:
0.68
Capitalizzazione di mercato:
$540.91M
Reddito:
$314.00K
Utile/perdita netta:
$-40.23M
Rapporto P/E:
-9.6429
EPS:
-0.28
Flusso di cassa netto:
$-84.71M
1 W Prestazione:
+1.50%
1M Prestazione:
+20.54%
6M Prestazione:
+94.24%
1 anno Prestazione:
+64.63%
Intervallo 1D:
$2.59
$2.71
Intervallo di 1 settimana:
$2.53
$2.785
Portata 52W:
$1.03
$2.985
Atai Life Sciences N V Stock (ATAI) Company Profile
Nome
Atai Life Sciences N V
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
WALLSTRASSE 16, BERLIN
Confronta ATAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
2.70 | 564.30M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Atai Life Sciences N V Borsa (ATAI) Ultime notizie
why atai life sciences n.v. stock attracts strong analyst attentionDaily Breakout Picks - Newser
Why Atai Life Sciences N.V. stock attracts strong analyst attentionMarket Timing Advice - Newser
How Atai Life Sciences N.V. stock performs during market volatilityMomentum Swing Watchlist - Newser
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target - Yahoo Finance
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atai Life Sciences, Beckley Psytech Announce Positive Topline Results for BPL-003 - Yahoo Finance
atai Life Sciences stock rating reiterated at Buy by Aegis Capital - Investing.com Australia
atai Life Sciences stock maintains Buy rating after positive Phase 2b results - Investing.com
atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data - Investing.com Canada
Biotech Rips On Dual Announcement - The Globe and Mail
Atai Life Sciences’ Merger Sparks Market Buzz - timothysykes.com
Atai Life Sciences To Raise $50 Mln Via Private Placement To Fund Clinical Programs; Stock Up - Nasdaq
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June - Benzinga
Atai Life Sciences N.V. announced that it expects to receive $50 million in funding - MarketScreener
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? - Yahoo Finance
Psychedelic medicine stocks fall following Compass depression asset data (ATAI:NASDAQ) - Seeking Alpha
ATAI Sees Potential Boost from U.S. Policy Shift on Psychedelics - GuruFocus
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire Inc.
ATAI’s Stock Dilemma: ATAI Life Sciences N.V’s Market Performance and Outlook - investchronicle.com
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com
Atai Life Sciences (ATAI) Garnered a Buy Rating and $12 Target | ATAI Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Yahoo Finance
Lucid Capital Markets initiates coverage on atai Life Sciences stock By Investing.com - Investing.com Nigeria
ATAI Gains Buy Rating and Price Target from Lucid Capital | ATAI Stock News - GuruFocus
Lucid Capital Markets initiates coverage on atai Life Sciences stock - Investing.com
ATAI and Beckley Psytech Set to Merge in Strategic All-Share Dea - GuruFocus
Regeneron makes obesity push; Atai, Alto ink brain drug deals - Yahoo Finance
Atai Life Sciences Merges With Beckley Psytech In Major Shakeup - Finimize
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders - Morningstar
H.C. Wainwright maintains buy rating on atai Life Sciences stock By Investing.com - Investing.com India
H.C. Wainwright maintains buy rating on atai Life Sciences stock - Investing.com
atai Life Sciences (ATAI) Merges with Beckley Psytech for Psyche - GuruFocus
atai Life Sciences and Beckley Psytech merging - Seeking Alpha
Atai Life Sciences, Beckley Psytech to Merge in All-Stock Transaction - marketscreener.com
Transcript : Atai Life Sciences N.V., Beckley Psytech LimitedM&A Call - marketscreener.com
Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley - Bloomberg
Atai Life Sciences N V Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.40%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):